Actavis Expands Manufacturing Operations in Puerto Rico
Actavis develops a solid dosage manufacturing and packing facility at its Manati site in Puerto Rico.
The Puerto Rico Industrial Development Company (PRIDCo) and Actavis announced that the company will develop a solid dosage manufacturing and packing facility at its Manati site and expand its current hormone production in Fajardo.
Actavis is investing $48 million and has committed to create up to 300 new jobs over a 36-month period; it has already has created 100 jobs. The investment will allow the company to bring new lines of generic, brand, and biosimilar products. When the expansion is completed, Actavis will have 700 employees in Puerto Rico.
All plans are expected to be complete by 2016.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
